MedTrace Logo

Effect of the Nasal Gel "Nascum®-Plus" on Allergic Symptoms

NCT03772405 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2019-02-15

No results posted yet for this study

Summary

The aim of this study is to assess if a physical barrier, created by the nasal gel Nascum®- Plus, is able to prevent or minimize the induction of nasal symptoms during allergen challenge in the Fraunhofer Allergen Challenge Chamber (ACC). Furthermore, the effect on soluble and cellular inflammatory markers induced by the allergic reaction will be assessed. Nascum®-Plus contains no active pharmaceutical ingredient, only monographed pharmaceutical excipients.

Conditions

  • Rhinitis, Allergic, Seasonal

Interventions

DRUG

Nascum Plus

nasal application of nascum plus

OTHER

ACC

4 hours challenge to grass pollen in the allergen challenge chamber (ACC)

Sponsors & Collaborators

  • M et P Pharma AG

    collaborator UNKNOWN

  • Fraunhofer-Institute of Toxicology and Experimental Medicine

    lead OTHER

Principal Investigators

  • Philipp Badorrek, MD · The Fraunhofer-Gesellschaft

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-12
Primary Completion
2019-02-01
Completion
2019-02-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03772405 on ClinicalTrials.gov